NovaBiotics Receives Orphan Drug Status from the FDA for Lynovex for the Treatment of Cystic Fibrosis

NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for Lynovex® (NM001), the Company’s first-in-class  therapeutic candidate for the treatment of Cystic Fibrosis (CF). CF is a … Continued

CF Trust partners with NovaBiotics Ltd and Health Sciences Scotland for development of Lynovex

Lynovex®, a recognised treatment for a non CF-related condition, is being developed as a treatment for persistent lung infection in cystic fibrosis, thanks to a partnership between the Cystic Fibrosis Trust, Health Sciences Scotland and biotech company NovaBiotics Ltd. The … Continued